Abstract
5. UNICEF/UNAIDS/WHO/MSF. Sources and prices of selected drugs and diagnostics for people living with HIV/AIDS. Geneva: World Health Organization; 2002. WHO document WHO/EDM/PAR/2002.2. 6. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802. 7. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-68. 8. Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, et al. Cost effectiveness of a single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999;353:803-9. 9. Sinkala M, Stout JP, Vermund SH, Goldenberg RL, Stringer JSA. Zambian women’s attitudes towards mass nevirapine therapy to prevent perinatal transmission of HIV. Lancet 2001;358:1611-2. 10. Stringer JSA, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence resource-poor settings. Journal of Acquired Immune Deficiency Syndromes 2003;32:506-13. 11. Use of nevirapine among women of unknown serostatus. Report of a technical consultation, Geneva, 5–6 December 2001. Geneva: World Health Organization; 2002. 12. Mofenson L.M., Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. Journal of Acquired Immune Deficiency Syndromes 2002;30:200-15. 13. Jackson JB, Barnett S, Piwowar-Manning E, Apuzzo L, Raines C, Hendrix C, et al. A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS 2003;17:547-53. 14. Jourdain G, Ngo-Giang-Huong N, Tungyai P, Kummee A, Bowonwatanuwong C, Kantipong P, et al. Exposure to intrapartum single-dose nevirapine and subsequent maternal 6-month response to NNRTI-based regimens. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections; 8–11 February 2004, San Francisco (CA). Abstract 41 LB; available from: http://www.retroconference.org/Search_Abstract_2004/ 15. Martinson N, Morris L, Gray G, Moodley D, Lupondwana P, Chezzi C, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections; 8–11 February 2004, San Francisco (CA). Abstract No. 38; available from: http://www.retroconference.org/ Search_Abstract_2004/ 16. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-7. 17. Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva: World Health Organization; 2004.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
